On The Fly
|
Check out this morning's… ShowHide Related Items >><< - 03/23/21
- Roche says phase 3 COVID-19 antibody cocktail trial met primary endpoint
- 03/22/21
- Genentech to discontinue dosing in Phase III GENERATION HD1 study
- 03/22/21
- Genentech: Tecentriq met primary endpoint in Phase III Mpower010 study
- 03/22/21
- QuantumScape drops 8% to $59.31 after 13M share common stock offering
- 02/17/21
- QuantumScape rises 11.3%
- 02/17/21
- QuantumScape rises 10.8%
- 01/31/21
- Fly Intel: Top five weekend stock stories
- 03/23/21
- Oramed confirms screening of first patients in ORA-D-013-2 study
- 03/23/21
- Oramed jumps 30% to $13.50 after announcing first screening in ORMD-0801 study
- 03/23/21
- Oramed screens first patient in ORA-D-013-2 study
- 03/19/21
- Oramed, Premas announce development of oral COVID-19 vaccine candidate
- 02/16/21
- Cooperman's Omega Advisors buys GM, exits Lee in Q4
- 12/29/20
- MP Materials falls -12.5%
- 12/29/20
- MP Materials falls -8.9%
- 12/17/20
- MP Materials rises 11.0%
IONS Ionis Pharmaceuticals - 03/22/21
- Ionis Pharmaceuticals trading resumes
- 03/22/21
- Ionis Pharmaceuticals: Roche to discontinue dosing in Phase 3 GENERATION HD1
- 03/22/21
- Ionis Pharmaceuticals trading halted, news pending
- 03/08/21
- Tracon Pharmaceuticals appoints Lisa Johnson-Pratt to board of directors
FREQ Frequency Therapeutics - 03/23/21
- Frequency Therapeutics releases new data from two FX-322 clinical studies
- 02/22/21
- Frequency Therapeutics reports publication of FX-322 Phase 1/2 study results
- 01/19/21
- Frequency Therapeutics appoints Quentin McCubbin as chief manufacturing officer
- 12/01/20
- Frequency Therapeutics names Peter Pfreundschuh as new CFO
- 03/22/21
- Starboard discloses 7.0% activist stake in eHealth
- 03/11/21
- eHealth enters cooperation agreement with Hudson Executive Capital
- 02/19/21
- eHealth up 2% after Hudson raises stake to 5.8%, says make engage in talks
- 01/29/21
- eHealth announces strategic $225M investment from H.I.G. Capital
- 03/22/21
- Chiasma presents long term safety, efficacy data for Mycapssa
- 03/21/21
- Chiasma presents new data for MYCAPSSA from Phase 3 trial MPOWERED
- 01/19/21
- Chiasma appoints John Doyle as CFO
- 01/06/21
- Chiasma provides update, sees FY21 operating expenses $80M-90M
- 03/22/21
- BioLife Solutions to acquire Stirling Ultracold in an all-stock merger
- 03/22/21
- BioLife Solutions to acquire Stirling Ultracold in an all-stock merger
- 02/16/21
- BioLife Solutions promotes Marcus Schulz to Chief Revenue Officer
- 12/01/20
- BioLife Solutions participates in iVexSol Series A Funding
- 03/23/21 Credit Suisse
- eHealth price target raised to $78 from $63 at Credit Suisse
- 03/23/21 Evercore ISI
- eHealth price target raised to $80 from $60 at Evercore ISI
- 02/19/21
- Fly Intel: Top five analyst downgrades
- 02/19/21 Deutsche Bank
- eHealth downgraded to Hold on 'credibility gap' at Deutsche Bank
- 03/23/21 Maxim
- BioLife Solutions price target raised to $60 from $40 at Maxim
- 03/23/21 KeyBanc
- BioLife Solutions price target raised to $50 from $40 at KeyBanc
- 03/23/21 Northland
- BioLife Solutions acquisition of Stirling a 'major positive,' says Northland
- 03/23/21 Stephens
- BioLife Solutions price target raised to $55 from $50 at Stephens
- 12/03/20 Alliance Global Partners
- Oramed initiated with a Buy at Alliance Global Partners
- 07/13/20 H.C. Wainwright
- Oramed price target raised to $17 from $16 at H.C. Wainwright
- 06/22/20 H.C. Wainwright
- Oramed price target lowered to $16 from $20 at H.C. Wainwright
FREQ Frequency Therapeutics - 02/11/21 Oppenheimer
- Frequency Therapeutics price target raised to $68 from $48 at Oppenheimer
- 01/27/21
- Fly Intel: Top five analyst upgrades
- 01/27/21 JPMorgan
- JPMorgan upgrades Frequency Therapeutics ahead of 'transformational' data
- 01/27/21 JPMorgan
- Frequency Therapeutics upgraded to Overweight from Neutral at JPMorgan
IONS Ionis Pharmaceuticals - 03/23/21 BMO Capital
- Ionis Pharmaceuticals price target lowered to $76 from $90 at BMO Capital
- 03/23/21 Cowen
- Ionis Pharmaceuticals HD program halt removes overhang, says Cowen
- 03/23/21 Morgan Stanley
- Ionis Pharmaceuticals price target lowered to $43 from $50 at Morgan Stanley
- 03/23/21 Barclays
- Ionis Pharmaceuticals price target lowered to $47 from $52 at Barclays
- 03/23/21 RBC Capital
- Ionis Pharmaceuticals price target lowered to $65 from $76 at RBC Capital
- 03/17/21 BTIG
- GenMark downgraded to Neutral from Buy at BTIG
- 03/10/21 Cowen
- MP Materials initiated with an Outperform at Cowen
- 03/09/21 Deutsche Bank
- MP Materials downgraded to Hold on valuation at Deutsche Bank
- 03/08/21 Deutsche Bank
- MP Materials downgraded to Hold from Buy at Deutsche Bank
- 03/02/21
- Fly Intel: Top five analyst initiations
- 03/08/21 Cowen
- Cowen bullish on battery technology, starts QuantumScape at Outperform
- 03/08/21 Cowen
- QuantumScape initiated with an Outperform at Cowen
- 03/04/21 Baird
- QuantumScape initiated with a Neutral at Baird
- 02/11/21 Morgan Stanley
- QuantumScape initiated with an Overweight at Morgan Stanley
- 03/02/21 H.C. Wainwright
- Chiasma price target raised to $12 from $10 at H.C. Wainwright
- 01/11/21 Piper Sandler
- Chiasma price target lowered to $15 from $19 at Piper Sandler
- 11/05/20 Piper Sandler
- Chiasma reports first Mycapssa sales, strong cash balance, says Piper Sandler
- 08/31/20 Piper Sandler
- Piper sees strong demand for Chiasma's oral acromegaly therapy
- 02/04/21
- Roche reports 2020 core EPS CHF 19.16 vs. CHF 20.16 last year
- 10/27/20
- Oncolytics announces new GI cancer study using
- 10/15/20
- Roche confirms outlook for 2020 based on assessment of COVID-19
- 10/15/20
- Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year
- 11/24/20
- Oramed screens firts patientes in global Phase 3 trials of ORMD-0801
- 03/18/21
- MP Materials reports Q4 EPS 20c, consensus 5c
IONS Ionis Pharmaceuticals - 02/24/21
- Ionis Pharmaceuticals sees 2021 revenue over $600M, consensus $781.31M
- 02/24/21
- Ionis Pharmaceuticals reports Q4 EPS ($2.44), consensus 28c
- 11/04/20
- Ionis Pharmaceuticals reports Q3 EPS (22c), consensus (9c)
FREQ Frequency Therapeutics - 11/16/20
- Frequency Therapeutics reports Q3 EPS (16c), consensus (28c)
- 02/18/21
- eHealth sees FY21 adjusted EPS $2.77-$3.26 , consensus $3.92
- 02/18/21
- eHealth reports Q4 adjusted EPS $2.32, consensus $2.84
- 02/18/21
- Notable companies reporting after market close
- 01/29/21
- eHealth sees Q4 revenue $291.0M-$293.0M, consensus $369.24M
- 03/04/21
- Chiasma reports Q4 EPS (32c), consensus (35c)
- 11/05/20
- Chiasma reports Q3 EPS (30c), consensus (39c)
- 03/22/21
- BioLife Solutions sees FY21 revenue $101M-$110M, consensus $69.48M
- 03/22/21
- BioLife Solutions reports Q4 adjusted EPS (1c), consensus (2c)
- 11/05/20
- BioLife Solutions reports Q3 non-GAAP EPS 2c, consensus (2c)
|
On The Fly
|
Check out this evening's… ShowHide Related Items >><< - 01/10/21
- Exagen expects Q4 testing revenue between $10.5M-$10.8M
- 12/29/20
- Exagen amends co-promotion agreement with Janssen
- 11/16/20
- Exagen extends collaboration agreement with GlaxoSmithKline
- 11/02/20
- Exagen to evaluate emergence of autoimmune diseases after COVID-19
- 11/10/20
- Western Midstream rises 10.6%
- 11/10/20
- Western Midstream rises 12.2%
- 11/09/20
- Western Midstream sees FY21 CapEx $275M-$375M
- 11/09/20
- Western Midstream sees FY21 adjusted EBITDA $1.825B-$1.925B
VRCA Verrica Pharmaceuticals - 03/17/21
- Verrica Pharmaceuticals announces exclusive licensing agreement with Torii
- 03/04/21
- Verrica Pharmaceuticals expects cash to support operations at least into 1Q22
- 03/04/21
- Verrica says Torii exercises option to acquire license for VP-102
- 03/04/21
- Verrica Pharmaceuticals resubmits NDA for VP-102
- 03/22/21
- Raven falls 7% to $33.50 after Q4 earnings miss
- 02/24/21
- Raven names Taimur Sharih as new CFO
- 11/24/20
- Raven CEO says company 'well-positioned for substantial long-term growth'
- 03/22/21
- QuantumScape drops 8% to $59.31 after 13M share common stock offering
- 02/17/21
- QuantumScape rises 11.3%
- 02/17/21
- QuantumScape rises 10.8%
- 01/31/21
- Fly Intel: Top five weekend stock stories
- 01/11/21
- Piedmont Lithium announces strategic partnership with Sayona Mining
- 12/09/20
- Piedmont Lithium announces intent to re-domicile to United States
- 12/03/20
- Piedmont Lithium receives key permit for chemical operations
- 11/17/20
- Piedmont Lithium expands current drilling campaign
- 02/16/21
- Cooperman's Omega Advisors buys GM, exits Lee in Q4
- 12/29/20
- MP Materials falls -12.5%
- 12/29/20
- MP Materials falls -8.9%
- 12/17/20
- MP Materials rises 11.0%
- 03/22/21
- Kodak announces commitment from ONLINEPRINTERS Group
- 03/08/21
- Tom Golisano / GO EK Ventures IV takes 8.74% stake in Eastman Kodak
- 03/01/21
- Bluetree Group adopts Kodak SONORA X Process Free Plates
- 02/24/21
- Dealmed announces licensing agreement with Eastman Kodak
IONS Ionis Pharmaceuticals - 03/22/21
- Ionis Pharmaceuticals trading resumes
- 03/22/21
- Ionis Pharmaceuticals: Roche to discontinue dosing in Phase 3 GENERATION HD1
- 03/22/21
- Ionis Pharmaceuticals trading halted, news pending
- 03/08/21
- Tracon Pharmaceuticals appoints Lisa Johnson-Pratt to board of directors
- 01/19/21
- Guild Holdings falls -8.5%
- 03/22/21
- BioLife Solutions to acquire Stirling Ultracold in an all-stock merger
- 03/22/21
- BioLife Solutions to acquire Stirling Ultracold in an all-stock merger
- 02/16/21
- BioLife Solutions promotes Marcus Schulz to Chief Revenue Officer
- 12/01/20
- BioLife Solutions participates in iVexSol Series A Funding
- 12/28/20 Northland
- BioLife Solutions price target raised to $55 from $35 at Northland
- 11/09/20 KeyBanc
- BioLife Solutions initiated with an Overweight at KeyBanc
- 10/19/20 B. Riley
- BioLife Solutions price target raised to $35.50 from $30 at B. Riley Securities
- 09/23/20 B. Riley
- BioLife Solutions price target raised to $30 from $25.50 at B. Riley FBR
- 01/19/21 JPMorgan
- Guild Holdings downgraded to Neutral with $18.50 target at JPMorgan
- 01/19/21 JPMorgan
- Guild Holdings downgraded to Neutral from Overweight at JPMorgan
- 11/16/20
- Fly Intel: Top five analyst initiations
- 11/16/20 Compass Point
- Compass Point starts Guild Holdings at Buy with $20 price target
- 03/08/21
- Fly Intel: Top five analyst initiations
- 03/08/21 Raymond James
- Viant initiated with a Market Perform at Raymond James
- 03/08/21 Canaccord
- Viant initiated with a Buy, $52 price target at Canaccord
- 03/08/21 Needham
- Viant initiated with a Buy at Needham
- 03/19/21 Lake Street
- Raven initiated with a Buy at Lake Street
- 06/19/20
- Fly Intel: Top five analyst initiations
- 06/19/20 Oppenheimer
- Raven initiated with an Outperform at Oppenheimer
- 06/18/20 Oppenheimer
- Raven initiated with an Outperform at Oppenheimer
IONS Ionis Pharmaceuticals - 03/01/21 Barclays
- Ionis Pharmaceuticals upgraded to Equal Weight from Underweight at Barclays
- 02/24/21 Piper Sandler
- Ionis Pharmaceuticals price target lowered to $55 from $60 at Piper Sandler
- 12/28/20 Piper Sandler
- Ionis partner data inconclusive in Huntington's disease, says Piper Sandler
- 12/24/20 Benchmark
- Ionis starting to be treated as M&A target, says Benchmark
- 03/17/21 Cowen
- Exagen price target raised to $26 from $21 at Cowen
- 12/29/20 Cantor Fitzgerald
- Exagen amended Janssen terms removes uncertainty, says Cantor Fitzgerald
- 11/09/20 KeyBanc
- Exagen initiated with an Overweight at KeyBanc
- 10/07/20 BTIG
- Exagen assumed with a Buy at BTIG
- 03/08/21 Cowen
- Cowen bullish on battery technology, starts QuantumScape at Outperform
- 03/08/21 Cowen
- QuantumScape initiated with an Outperform at Cowen
- 03/04/21 Baird
- QuantumScape initiated with a Neutral at Baird
- 02/11/21 Morgan Stanley
- QuantumScape initiated with an Overweight at Morgan Stanley
- 03/04/21 B. Riley
- Piedmont Lithium price target raised to $93 from $66 at B. Riley Securities
- 02/09/21 Evercore ISI
- Evercore boosts Piedmont Lithium target to $75, sees path to $90 per share
- 01/25/21 B. Riley
- Piedmont Lithium initiated with a Buy at B. Riley Securities
- 01/22/21
- Fly Intel: Top five analyst initiations
- 03/10/21 Cowen
- MP Materials initiated with an Outperform at Cowen
- 03/09/21 Deutsche Bank
- MP Materials downgraded to Hold on valuation at Deutsche Bank
- 03/08/21 Deutsche Bank
- MP Materials downgraded to Hold from Buy at Deutsche Bank
- 03/02/21
- Fly Intel: Top five analyst initiations
- 03/12/21 JPMorgan
- Western Midstream upgraded to Overweight from Neutral at JPMorgan
- 03/05/21 Barclays
- Western Midstream price target raised to $22 from $19 at Barclays
- 02/01/21 Scotiabank
- Western Midstream resumed with a Sector Perform at Scotiabank
- 01/26/21 BofA
- Western Midstream upgraded to Neutral from Underperform at BofA
VRCA Verrica Pharmaceuticals - 03/08/21 H.C. Wainwright
- Verrica Pharmaceuticals price target raised to $24 from $21 at H.C. Wainwright
- 12/24/20 Cowen
- Verrica approval for molluscum likely in Q3 of 2021, says Cowen
- 12/24/20 H.C. Wainwright
- Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
- 07/15/20 BofA
- Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA
- 03/16/21
- Exagen sees FY21 revenue $47M-$49M, consensus $52.64M
- 03/16/21
- Exagen reports Q4 EPS (27c), consensus (40c)
- 11/10/20
- Exagen reports Q3 EPS (34c), consensus (48c)
- 02/23/21
- Western Midstream sees FY21 adjusted EBITDA $1.825B-$1.925B
- 02/23/21
- Western Midstream reports Q4 EPS 62c, consensus 58c
- 11/09/20
- Western Midstream reports Q3 EPS 55c, consensus 50c
VRCA Verrica Pharmaceuticals - 03/04/21
- Verrica Pharmaceuticals reporrts Q4 EPS (52c), consensus (42c)
- 11/09/20
- Verrica Pharmaceuticals reports Q3 EPS (42c), consensus (43c)
- 03/22/21
- Raven reports Q4 EPS 1c, two estimates 11c
- 11/24/20
- Raven Industries reports Q3 EPS 24c, consensus 12c
- 03/18/21
- MP Materials reports Q4 EPS 20c, consensus 5c
- 11/10/20
- Eastman Kodak report Q3 net loss ($445M) vs. ($5M) last year
IONS Ionis Pharmaceuticals - 02/24/21
- Ionis Pharmaceuticals sees 2021 revenue over $600M, consensus $781.31M
- 02/24/21
- Ionis Pharmaceuticals reports Q4 EPS ($2.44), consensus 28c
- 11/04/20
- Ionis Pharmaceuticals reports Q3 EPS (22c), consensus (9c)
- 03/22/21
- Guild Holdings reports Q4 adjusted EPS $1.49, consensus $1.84
- 12/02/20
- Guild Holdings reports Q3 revenue $563.5M, consensus $571.56M
- 03/22/21
- Viant sees FY21 revenue $194M-$200M, consensus $189.02M
- 03/22/21
- Viant sees Q1 revenue $38M-$38.5M, consensus $36.27M
- 03/22/21
- Viant reports Q4 EPS $12.86, consensus $10.33
- 03/22/21
- BioLife Solutions sees FY21 revenue $101M-$110M, consensus $69.48M
- 03/22/21
- BioLife Solutions reports Q4 adjusted EPS (1c), consensus (2c)
- 11/05/20
- BioLife Solutions reports Q3 non-GAAP EPS 2c, consensus (2c)
|
Syndicate
|
MP Materials Corp.… MP Materials Corp. announced the commencement, subject to market and other conditions, of a proposed registered secondary public offering of 8M shares of common stock by certain existing stockholders of the company. Deutsche Bank Securities and BofA Securities are acting as joint lead book-running managers for the proposed offering. Morgan Stanley and Cowen are acting as joint book-running managers for the offering. ShowHide Related Items >><< - 02/16/21
- Cooperman's Omega Advisors buys GM, exits Lee in Q4
- 12/29/20
- MP Materials falls -12.5%
- 12/29/20
- MP Materials falls -8.9%
- 12/17/20
- MP Materials rises 11.0%
- 03/10/21 Cowen
- MP Materials initiated with an Outperform at Cowen
- 03/09/21 Deutsche Bank
- MP Materials downgraded to Hold on valuation at Deutsche Bank
- 03/08/21 Deutsche Bank
- MP Materials downgraded to Hold from Buy at Deutsche Bank
- 03/02/21
- Fly Intel: Top five analyst initiations
- 03/18/21
- MP Materials reports Q4 EPS 20c, consensus 5c
- 03/18/21
- Fly Intel: After-Hours Movers
- 03/04/21
- MP Materials call volume above normal and directionally bullish
- 02/18/21
- Unusually active option classes on open February 18th
- 02/16/21
- MP Materials call volume above normal and directionally bullish
- 02/09/21
- MP Materials call volume above normal and directionally bullish
|
On The Fly
|
Check out this evening's… ShowHide Related Items >><< TRIL Trillium Therapeutics - 01/12/21
- Pfizer invests $120M in four clinical-stage biotech companies
- 11/16/20
- Trillium Therapeutics reports Q3 EPS (58c), consensus (90c)
- 11/02/20
- Trillium Therapeutics appoints Ingmar Bruns M.D as Chief Medical Officer
- 11/02/20
- Trillium Therapeutics announced the formation of a Scientific Advisory Board
- 03/18/21
- Sarepta reports new results from ongoing SRP-9003 study
- 02/25/21
- Sarepta rallies 2% to $86.15 after winning FDA approval for DMD treatment
- 02/25/21
- Sarepta announces FDA approval of Amondys 45
- 02/08/21
- Dyne Therapeutics appoints Ashish Dugar as SVP, global head of medical affairs
ROAD Construction Partners - 03/02/21
- Construction Partners: Fred Smith, III to succeed Charles Owens as CEO
- 02/05/21
- Construction Partners reports project backlog at December 31, 2020 of $655.6M
- 02/05/21
- Construction Partners maintains FY21 outlook
- 12/11/20
- Construction Partners CEO says 'well-positioned for continued growth' in FY21
OLLI Ollie's Bargain Outlet - 03/18/21
- Ollie's Bargain Outlet not providing Q1, FY21 guidance
- 03/18/21
- Ollie's Bargain announces $100M increase to company's share repurchase pact
- 12/15/20
- Ollie's Bargain Outlet announces $100M increase to share repurchase plan
- 12/03/20
- Ollie's Bargain Outlet falls 14% to $77.30 after Q3 results
- 03/18/21
- Nike down 2.5% below $140 per share after Q3 results, Q4 earnings call guidance
- 03/18/21
- Nike says exceeding pre-pandemic levels of business when looking out to FY22
- 03/18/21
- Nike CFO says EMEA inventory to be normalized by Q1 of 2022 if pandemic eases
- 03/18/21
- Nike CFO says expect to capture 'delayed' revenue from Q3 disruptions in Q4
- 02/16/21
- Cooperman's Omega Advisors buys GM, exits Lee in Q4
- 12/29/20
- MP Materials falls -12.5%
- 12/29/20
- MP Materials falls -8.9%
- 12/17/20
- MP Materials rises 11.0%
IDRA Idera Pharmaceuticals - 03/18/21
- Idera Pharmaceuticals trading resumes
- 03/18/21
- Idera Pharmaceuticals announces ILLUMINATE-301 trial misses primary endpoint
- 03/18/21
- Idera Pharmaceuticals trading halted, news pending
- 11/17/20
- Idera Pharmaceuticals appoints Dan Soland COO
- 03/18/21
- FedEx expects margin gains in all transportation segments in Q4
- 03/18/21
- FedEx sees FY21 CapEx approximately $5.7B
- 03/18/21
- FedEx expects higher y/y revenue in transportation segments in Q4
- 03/18/21
- FedEx says 'exceedingly optimistic' about future, 'great momentum' out of Q3
- 03/10/21 Cowen
- MP Materials initiated with an Outperform at Cowen
- 03/09/21 Deutsche Bank
- MP Materials downgraded to Hold on valuation at Deutsche Bank
- 03/08/21 Deutsche Bank
- MP Materials downgraded to Hold from Buy at Deutsche Bank
- 03/02/21
- Fly Intel: Top five analyst initiations
TRIL Trillium Therapeutics - 11/18/20 Craig-Hallum
- Trillium Therapeutics price target raised to $21 from $15 at Craig-Hallum
- 11/04/20 Cowen
- Trillium ASH abstracts provide 'minimal updates', says Cowen
- 10/12/20 Evercore ISI
- Trillium Therapeutics initiated with an Outperform at Evercore ISI
- 10/05/20 Piper Sandler
- Patent fight likely to weigh on ALX Oncology shares NT, says Piper Sandler
- 03/12/21 Credit Suisse
- FedEx price target lowered to $350 from $368 at Credit Suisse
- 03/11/21 JPMorgan
- FedEx price target lowered to $340 from $350 at JPMorgan
- 01/07/21 Wolfe Research
- FedEx downgraded to Peer Perform from Outperform at Wolfe Research
- 12/30/20 Argus
- FedEx price target raised to $305 from $270 at Argus
OLLI Ollie's Bargain Outlet - 02/16/21 JPMorgan
- Ollie's Bargain Outlet price target raised to $109 from $105 at JPMorgan
- 01/20/21 Morgan Stanley
- Ollie's Bargain Outlet downgraded to Underweight at Morgan Stanley
- 01/14/21
- Fly Intel: Top five analyst downgrades
- 01/14/21 BofA
- Ollie's Bargain Outlet double-downgraded to Underperform from Buy at BofA
- 03/02/21 RBC Capital
- Sarepta price target lowered to $132 from $143 at RBC Capital
- 03/02/21 Piper Sandler
- Sarepta price target lowered to $130 from $140 at Piper Sandler
- 02/26/21 Mizuho
- Sarepta price target raised to $160 from $158 at Mizuho
- 02/25/21 Piper Sandler
- Piper says Sarepta's Amondys 45 approval comes with 'relatively clean label'
- 03/17/21 Cowen
- Nike price target raised to $173 from $170 at Cowen
- 03/16/21 BTIG
- Improving inventory and expanding margins at Nike to drive Q3 beat, says BTIG
- 03/15/21 Piper Sandler
- Piper Sandler a buyer of Nike into results, boosts target to $170
- 03/11/21 Morgan Stanley
- Nike price target trimmed to $173 ahead of earnings at Morgan Stanley
IDRA Idera Pharmaceuticals - 11/02/20 JPMorgan
- Idera Pharmaceuticals assumed with an Overweight at JPMorgan
- 09/01/20 Jefferies
- Checkmate Pharmaceuticals initiated with a Buy at Jefferies
ROAD Construction Partners - 12/14/20 DA Davidson
- Construction Partners price target raised to $25 from $18 at DA Davidson
- 12/14/20 Raymond James
- Construction Partners price target raised to $30 from $21.50 at Raymond James
- 09/17/20 Stifel
- Construction Partners initiated with a Buy at Stifel
- 08/25/20
- Fly Intel: Top five analyst downgrades
TRIL Trillium Therapeutics - 11/16/20
- Trillium Therapeutics reports 9M EPS ($2.19) vs. (93c) last year
- 03/01/21
- Sarepta reports Q4 EPS ($1.84), consensus ($1.77)
- 03/01/21
- Sarepta reports Q4 EPS ($1.84), consensus ($1.77)
- 11/05/20
- Sarepta reports Q3 EPS ($2.50), consensus ($1.71)
ROAD Construction Partners - 02/05/21
- Construction Partners reports Q1 EPS 15c, consensus 13c
- 12/11/20
- Construction Partners sees FY21 revenue $950M-$1B, consensus $859.25M
- 12/11/20
- Construction Partners reports Q4 EPS 34c, consensus 30c
- 10/23/20
- Construction Partners sees FY20 revenue $782M-$787M, consensus $809.93M
OLLI Ollie's Bargain Outlet - 03/18/21
- Ollie's Bargain Outlet reports Q4 EPS 97c, consensus 85c
- 12/03/20
- Ollie's Bargain Outlet reports Q3 adj. EPS 65c, consensus 58c
- 12/03/20
- Notable companies reporting after market close
- 03/18/21
- Nike CFO sees Q4 revenue growth up 75% from last year, consensus $10.37B
- 03/18/21
- Nike reports Q3 EPS 90c, consensus 76c
- 12/18/20
- Nike raises FY21 revenue growth view to low teens
- 03/18/21
- MP Materials reports Q4 EPS 20c, consensus 5c
IDRA Idera Pharmaceuticals - 03/01/21
- Idera Pharmaceuticals reports Q4 ex-items EPS (22c), consensus (23c)
- 10/29/20
- Idera Pharmaceuticals reports Q3 EPS (59c), consensus (22c)
- 03/18/21
- FedEx sees FY21 EPS $17.60-$18.20, consensus $17.40
- 03/18/21
- FedEx reports Q3 EPS $3.47, consensus $3.24
- 03/18/21
- Notable companies reporting after market close
- 12/17/20
- FedEx aims to increase EPS by 10%-15 per year over long term
|
Earnings
|
Reports Q4 revenue… Reports Q4 revenue $42.2M, consensus $37.5M. CEO James Litinsky said, "MP made significant progress throughout 2020 towards our mission to restore the full rare earth supply chain to the United States. In addition to strengthening our balance sheet through a successful business combination, we ramped up our production of rare earths by nearly 40%, scaled our team to over 300 people, and put in motion our Stage II optimization plan at Mountain Pass. The accelerating global transformation towards electrification and decarbonization is creating strong demand for critical rare earth materials. These trends present a bright outlook for the Company as we prepare to begin delivering separated rare earth oxides in 2022." ShowHide Related Items >><< - 02/16/21
- Cooperman's Omega Advisors buys GM, exits Lee in Q4
- 12/29/20
- MP Materials falls -12.5%
- 12/29/20
- MP Materials falls -8.9%
- 12/17/20
- MP Materials rises 11.0%
- 03/10/21 Cowen
- MP Materials initiated with an Outperform at Cowen
- 03/09/21 Deutsche Bank
- MP Materials downgraded to Hold on valuation at Deutsche Bank
- 03/08/21 Deutsche Bank
- MP Materials downgraded to Hold from Buy at Deutsche Bank
- 03/02/21
- Fly Intel: Top five analyst initiations
- 03/04/21
- MP Materials call volume above normal and directionally bullish
- 02/18/21
- Unusually active option classes on open February 18th
- 02/16/21
- MP Materials call volume above normal and directionally bullish
- 02/09/21
- MP Materials call volume above normal and directionally bullish
|